ArticleCancer cell2021

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity.

Ariella B Hanker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.